Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02397707 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics of Voxilaprevir in Adults With Normal Hepatic Function and Moderate or Severe Hepatic Impairment
A Phase 1 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT02397707 is a Phase 1 study that has completed, run by Gilead Sciences. The registered enrollment target is 33 participants.
The verdict
NCT02397707, a Phase 1 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the pharmacokinetics (PK), safety, and tolerability of a single dose of voxilaprevir (formerly GS-9857) in participants with normal hepatic function, moderate hepatic impairment and severe hepatic impairment. Participants in the healthy control group will be matched to participants with impaired hepatic function by gender, age (± 10 years), and body mass index (± 15%).
Interventions
- DRUG Voxilaprevir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2015-03-24 |
| Est. Completion | 2016-03-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02397707
The ClinicalTrials.gov registry entry for NCT02397707 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Voxilaprevir is the first listed.
NCT02397707 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02397707 about?
NCT02397707 is a clinical study titled "Pharmacokinetics of Voxilaprevir in Adults With Normal Hepatic Function and Moderate or Severe Hepatic Impairment". The primary objective of this study is to evaluate the pharmacokinetics (PK), safety, and tolerability of a single dose of voxilaprevir (formerly GS-9857) in participants with normal hepatic function, moderate hepatic impairment and severe hepatic impairment. Participants in the healthy control grou...
What is the current status of trial NCT02397707?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2015-03-24. Estimated completion is 2016-03-04.
What interventions are being tested in trial NCT02397707?
The interventions under investigation include: Voxilaprevir (DRUG).
Who is sponsoring clinical trial NCT02397707?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.